Summary:
To evaluate the role of high-dose melphalan and autologous transplant (AT) in reversing dialysis-dependent renal failure, 59 patients still on dialysis at the time of AT were analyzed. A total of 37 patients had been on dialysis ⩽6 months. A 5-year event-free and overall survival rate of all patients after AT was 24 and 36%, respectively. Of 54 patients evaluable for renal function improvement, 13 (24%) became dialysis independent at a median of 4 months after AT (range: 1–16). Dialysis duration ⩽6 months prior to first AT and pre-transplant creatinine clearance >10 ml/min were significant for renal function recovery: 12 of 36 (33%) ⩽6 months vs one of 18 patients (6%) >6 months on dialysis recovered renal function; 10 of 26 (38%) with >10 ml/min vs three of 28 (11%) with ⩽10 ml/min of creatinine clearance (both P<0.05). Quality of response after autotransplant was also significant: 12 of 31 (39%) being greater than partial remission after AT vs one of 21 patients (5%) attaining partial remission or less became independent of dialysis (P<0.05). Our data suggest that significant renal failure can be reversible and AT should be considered early in the disease course.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Knudsen LM, Hippe E, Hjorth M et al. Renal function in newly diagnosed multiple myeloma – a demographic study of 1353 patients. The Nordic Myeloma Study Group. Eur J Haematol 1994; 53: 207–212.
Knudsen LM, Hjorth M, Hippe E . Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol 2000; 65: 175–181.
Pichette V, Querin S, Desmeules M et al. Renal function recovery in end-stage renal disease. Am J Kidney Dis 1993; 22: 398–402.
Rota S, Mougenot B, Baudouin B et al. Multiple myeloma and severe renal failure: a clinicopathologic study of outcome and prognosis in 34 patients. Medicine 1987; 66: 126–137.
Komatsuda A, Wakui H, Ohtani H et al. Disappearance of nodular mesangial lesions in a patient with light chain nephropathy after long-term chemotherapy. Am J Kidney Dis 2000; 35: E9.
Pozzi C, Fogazzi GB, Banfi G et al. Renal disease and patient survival in light chain deposition disease. Clin Nephrol 1995; 43: 281–287.
Comenzo RL, Vosburgh E, Falk RH et al. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients. Blood 1998; 91: 3662–3670.
Badros A, Barlogie B, Siegel E et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 2001; 114: 822–829.
National Cancer Institute: Cancer Therapy Evaluation Program: Common Toxicity Criteria, version 2, Bethesda, MD, National Cancer Institute, April 30, 1999.
Gooley TA, Leisenring W, Crowley J, Storer BE . Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18: 695–706.
Hintze JL . Number Cruncher Statistical System 2001. NCSS Kaysville, UT.
Kaplan EL, Meier P . Nonparametric estimation from incomplete observation. Journal of the American Statistical Association 1958; 53: 457–481.
Collett D . Modeling Survival Data in Medical Research. Chapman & Hall: London, 1994.
Lee CK, Barlogie B, Zangari ME et al. D.T.PACE, an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol 2003; 21: 2732–2739.
Fassas AB, Spencer T, Desikan R et al. Cytotoxic chemotherapy following tandem autotransplants in multiple myeloma patients. Br J Haematol 2002; 119: 164–168.
Barlogie B, McCoy J, Shaughnessy J et al. Total therapy II (TT II) for newly diagnosed multiple myeloma (MM): preliminary data on feasibility and efficacy in the first 231 enrolled patients; Comparison with Predecessor Trial Total Therapy I (TT I) (N=231). Blood 2001; 98: 683 (abstract 2857).
Blade J, Fernandez-Llama P, Bosch F et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med 1998; 158: 1889–1893.
Torra R, Blade J, Cases A et al. Patients with multiple myeloma requiring long-term dialysis: presenting features, response to therapy, and outcome in a series of 20 cases. Br J Haematol 1995; 91: 854–859.
Tricot G, Alberts DS, Johnson C et al. Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study. Clin Cancer Res 1996; 2: 947–952.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lee, CK., Zangari, M., Barlogie, B. et al. Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant. Bone Marrow Transplant 33, 823–828 (2004). https://doi.org/10.1038/sj.bmt.1704440
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1704440
Keywords
This article is cited by
-
Autologous stem cell transplantation for multiple myeloma patients with chronic kidney disease: a safe and effective option
Bone Marrow Transplantation (2022)
-
The influence of high-efficiency particulate air filtration on mortality among multiple myeloma patients receiving autologous stem cell transplantation
Scientific Reports (2021)
-
Toxicity and survival outcomes of autologous stem cell transplant in multiple myeloma patients with renal insufficiency: an institutional comparison between two eras
Bone Marrow Transplantation (2020)
-
Multiples Myelom und renale Beteiligung
Der Nephrologe (2019)
-
Extending autologous transplantation as first line therapy in multiple myeloma patients with severe renal impairment: a retrospective study by the SFGM-TC
Bone Marrow Transplantation (2018)